David Baram

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

SmartZyme is a life science company using PROVOLUTION™ , a proprietary technological platform for protein design and engineering, in accordance with industry required specifications. The company was founded in November 2013 by Shilo Ben Zeev (CEO) and David Baram, Ph.D. (CTO). The company aims to efficiently design and create proteins and potent enzymes with the specific characteristics required for optimal performance. Its products will be used to revolutionize industries by addressing unmet needs of various industrial fields. The company’s PROVOLUTION™ technology combines some of the most advanced scientific tools for protein engineering, computational biology and electrochemistry. These tools enable the development of improved, or “superior”, proteins and enzymes for wide ranging applications. The Company is currently focusing on the Diabetes market where it intends to launch its first two products: a pre-designed enzyme with superior characteristics for improved bio-electrochemical glucose catalysis, to be used on glucose test strips for the Self Monitoring Blood Glucose (SMBG) market. Strip manufacturers incorporating this superior enzyme in their products will be able to offer results which are far more accurate than current standard strips and ensure that their strips meet the rigid ISO 15197:2013 requirements. The company’s second product, the Go Patch Go™, personalized patient care system (PCS), an on-demand blood glucose measurement system in which measurement accuracy, enzyme stability and product shelf life are significantly enhanced due to the use of SmartZyme’s protein engineering technology. This product will offer diabetic patients a solution to current blood glucose monitoring systems which lack the optimal accuracy and stability required for effective treatment for diabetes. SmartZyme’s R&D efforts are supported by a scientific advisory board of leaders in the fields of protein engineering, structural biology and electrochemistry.

MyBiotics is an innovative life science company active in the Microbiome field. The company develops Pharmabiotics products and drugs based on indication specific bacterial mix combined with its proprietary and highly efficient delivery technologies. MyBiotics developed a unique highly efficient live and colonizing bacteria delivery technologies MyCrobe and SuperDonor technologies allow highly efficient and clinically proven bacterial targeted release, these technology will be used for Microbiome restoration and a long list of medical indications. The company completed pre-clinical experiments and will start its clinical trials in 2016.

BASE is a unique platform for companies wishing to expand their activities to the Brazilian market. With a network covering 85% of Brazil's business regions and flexibility and versatility in our business methods, BASE is the perfect strategic partner for your company. Our activity in Brazil is focused in the fields of medical devices, cosmetics and food & beverages. Our team has more than a decade of experience in international business development, distribution, global management and logistics. We put our experience and expertise into forming a full, tailor made solution for companies expanding their business to South America in general and Brazil in particular. Our platform includes: Distribution networks Local Manufacturing Business Development Management Services Financing Regulatory Advisors Legal Counseling Technical Support

The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. The Institute has five faculties – Mathematics and Computer Science, Physics, Chemistry, Biochemistry and Biology – and the faculties in turn are divided into 17 scientific departments. Over the years, work by Institute scientists has widely expanded our knowledge in these areas, created new research fields, and combined traditional scientific disciplines in multidisciplinary studies that steer research into new, exciting and often surprising paths. In addition, the Weizmann School of Science, the Institute’s university arm, trains research students pursuing graduate degrees. Over the years, the Weizmann Institute has grown with the country, and it has been the site of numerous milestones in Israel’s science. Institute scientists were pioneers in the field of cancer research in Israel. Others planned and built the country’s first electronic computer, one of the first in the world; yet others founded the first nuclear physics department and erected a particle accelerator next door. They were the first to establish a company for transferring knowledge from academia to industry (YEDA Research and Development), and they initiated the founding of a science-based industrial park near the Institute.